Schizophrenia
Schizophrenia is a chronic mental disorder that typically manifests in young adulthood, characterized by reoccurring episodes of psychosis, including auditory or visual hallucinations, delusions, disorganized thinking and behavior, and social withdrawal. Diagnosis relies on behavioral observations, psychiatric history, and reports from acquaintances, with symptoms needing to be present for at least one to six months.
Health Outcomes
- Absence of Biogenic Amines Production
- Activation of G-Protein Coupled Receptors
- Altered Brain Activity to Negative Emotional Stimuli
- Altered Catecholamine Level
- Altered Monoamine Signaling
- Altered Neurobiological Markers
- Altered Pyridoxine Concentration
- Changed Functional Connectivity
- Comparable Tolerability
- Decreased Composite Scores
- Demonstrated Long-term Safety
- Elevated Serum Acetylcholine Levels
- Enhanced Adverse Event Reporting
- Enhanced BDNF-TrkB Signaling
- Enhanced Brain-Derived Neurotrophic Factor Levels
- Enhanced Neuropharmacological Function
- Enhanced Sensory Perception
- Improved Adherence Ability
- Improved Behavioral Abnormalities
- Improved Behavioral Elements
- Improved Behavioral Health
- Improved Cognitive Behavior
- Improved Cognitive Flexibility
- Improved Cognitive Score
- Improved Decision Accuracy
- Improved Decision-Making Accuracy
- Improved Depressive Symptoms
- Improved Distractor Interference
- Improved Emotional Well-Being Quality of Life
- Improved General Behavioral Scores
- Improved Global Clinical Impression
- Improved Global Clinical Status
- Improved Glutamate-Serine-Glycine Index
- Improved Gut-Brain Axis-Related Neuropsychiatric Health
- Improved Hippocampal Fractional Anisotropy
- Improved Medication Adherence
- Improved Mental Health
- Improved Mini-Mental State Examination Score
- Improved Negative Symptom
- Improved Neurobehavioral Function
- Improved Neuropsychiatric Outcomes
- Improved Neurotransmitter Metabolism
- Improved Neurotransmitter Profile
- Improved Problem-Solving Skills
- Improved Psychosocial Domain Score
- Improved Psychosocial Health-Related Quality of Life
- Improved Responder Rate
- Improved Schizophrenia
- Improved Set Shifting Ability
- Improved Set-Shifting
- Improved Set-Shifting Reaction Time
- Improved Social Emotional Cognition
- Improved Social Function
- Improved Social Functioning
- Improved Social Functioning Quality of Life
- Improved Socialization
- Improved Synaptic Plasticity
- Improved Therapeutic Consistency
- Improved Therapy Acceptability
- Improved Visual-Spatial Function
- Improved Working Memory
- Increased BDNF Levels in the Prefrontal Cortex
- Increased Brain Choline Level
- Increased Brain GABA Levels
- Increased Distractibility
- Increased Folate Levels
- Increased Locomotor Activity During Active Phase
- Increased Negative Transcriptional Regulation
- Increased Plasma Kynurenic Acid Levels
- Increased Plasma Tryptophan Concentration
- Increased Postsynaptic Density Protein 95 Levels
- Increased Prefrontal Cortex Deoxygenated Hemoglobin Level
- Increased Production of Beneficial Neurotransmitter GABA
- Increased Production of Biogenic Amines
- Increased Prolactin Level
- Increased Propionic Acid Levels
- Increased Propionic Acid Production
- Increased Serotonin 2A Receptor Levels
- Increased Serum BDNF Levels
- Increased Social Avoidance
- Modified Resting-State Brain Connectivity
- Modulated Endocannabinoid System
- Modulated Signal Transduction Pathways
- Neuroprotection Against Dopamine Neuronal Loss
- No CYP1A2 or CYP3A4 Interaction
- No Change in Appetite Parameters
- No Change in Plasma GABA Levels
- No Change in Serum Cytokine Levels
- No Difference in Adverse Events
- No Significant Impact on Bacterial Community Composition or Diversity
- Normalized Neurotransmitter Levels
- Reduced Adherence Attrition
- Reduced Anhedonia
- Reduced Cognitive Function
- Reduced Confusion and Bewilderment
- Reduced Cortical Excitation
- Reduced D-Tryptophan Levels
- Reduced DOPAC Levels in Amygdaloid Cortex
- Reduced Dopamine Levels
- Reduced Glutamate Level
- Reduced Gut Bacteria Associated with Mental Illness
- Reduced Hippocampal Apoptosis
- Reduced Indoleamine 2,3-Dioxygenase Activity
- Reduced Interference Score on Simon Task
- Reduced Kynurenine-Tryptophan Ratio
- Reduced N-acetylaspartate Level
- Reduced Negative Symptom Score
- Reduced Negative Symptoms
- Reduced Perseverative Error
- Reduced Plasma LPS Levels
- Reduced Positive Symptom
- Reduced Positive Symptom Score
- Reduced Prefrontal Cortex Oxygenated Hemoglobin
- Reduced Prefrontal Cortex Total Hemoglobin Level
- Reduced Psychological Score
- Reduced Psychopathology Symptoms
- Reduced Rearing Behavior
- Reduced Relapse Rate
- Reduced Response Time on Flanker Task
- Reduced Serum BDNF Levels
- Reduced Serum Glutamate Levels
- Reduced Set-Shifting Reversal Error
- Reduced Simple Reaction Time
- Reduced Total PANSS Score
- Reduced Total Side Effects Incidence
- Reduced cFos Expression in Brain Areas
- Regulated Microglial Activation
- Regulation of Neuroactive Ligand Receptor Interaction Pathway
- Stabilized Dopamine Pathway Function
- Stable Brain Metabolite Levels
- Unchanged Risk of Sepsis